Saxenda® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) and in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs.
Saxenda® (liraglutide) injection
The search will retrieve any scientific documents from the medical information database where the search terms match either the title or content of the document. The response(s) are not intended to offer recommendations for administering Novo Nordisk products in a manner inconsistent with approved labeling. To access the Prescribing Information for Novo Nordisk products, please click here.
Search for Letters
Find documents for this product by entering your search terms in the box below.
Have a Question?
Request information directly from the Novo Nordisk
Medical Information department.
Have a Question?
All fields required.